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Abstract Pediatric migraine is a disabling condition,
which can cause a significant impact on quality of life.
Currently, no drugs have been approved by the FDA for its
preventive treatment. Our aim was to review the medical
literature concerning the efficacy and tolerability of topi-
ramate in the prophylactic treatment of migraine in
children and adolescents. A total of five papers were
reviewed: two randomized controlled trials (RCTs), a post-
hoc subset analysis of adolescents who had been included
in three RCTs carried out on adults and two open studies.
Topiramate has been proven to reduce headache frequency
and the accompanying disability. The frequency of side
effects varied considerably among studies, the most fre-
quent being weight loss, anorexia, abdominal pain,
difficulties in concentrating, sedation and paresthesia.
Since these adverse events, although often transitory, may
be distressing for the child, we strongly recommend to
assess the disability caused by the migraine episodes before
deciding to initiate a prophylactic treatment. Nevertheless,
dropout rates due to side effects in the studies were very
low.
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Introduction
Pediatric migraine is a disabling condition, which can
cause a significant impact on quality of life. It can nega-
tively influence the child’s school performances, social and
family life and often causes school absenteeism. Migraine
prevalence in childhood ranges from 2.7 to 10% [1]. About
3–5% of school-aged children suffer from migraine and
this proportion gradually increases to 20% through ado-
lescence. Initially, there is a slight male predominance;
however, through adolescence, there is a shift toward
female predominance, which remains through adulthood
[2, 3].
Management of pediatric migraine includes lifestyle
changes (in order to avoid foods, habits or enviromental
factors that may trigger a migraine attack), the use of
abortive medications and preventive measures, which can
be either nonpharmacological or pharmacological. Guide-
lines addressing the indications for the use of preventive
measures in children are lacking, but to date, most authors
recommend preventive measures in children when head-
ache frequency exceeds three to four episodes per month
and/or the attacks are significantly disabling, as measured
in scoring systems such as the Pediatric Migraine Dis-
ability Assessment Scale (PedMIDAS) [4, 5]. PedMIDAS
is a validated six-item questionnaire based on the adult
MIDAS tool [6] with developmentally appropriate changes
and adjustments for childhood lifestyle. The questions deal
with the impact of headache on school (school day
absences, partial day absences, functioning at 50% or less
ability in school), on household acitivities (ability to per-
form homework and chores) and on social functioning
(including sports) [7, 8]. The assessment of migraine dis-
ability is particularly important in children to correctly
evaluate and treat migraine.
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Currently, no drugs have been approved by the Food and
Drug Administration (FDA) for the preventive treatment of
pediatric migraine. Topiramate is an antiepileptic drug,
which has been approved by the FDA in the United States
and in many other countries for the preventive treatment of
migraine in adults and for the treatment of partial-onset
seizures and primary generalized tonic–clonic seizures as
add-on therapy in children as young as 2 years. Our aim
was to review the medical literature concerning the efficacy
and tolerability of topiramate in the prophylactic treatment
of migraine in children and adolescents.
Materials and methods
We searched Pubmed (1966–July 2007) using the following
keywords: ‘‘topiramate’’ + ‘‘headache’’ or ‘‘migraine’’ +
‘‘children’’ or ‘‘adolescents’’ or ‘‘pediatric.’’ We included
randomized controlled trials (RCT), open-label trials and
retrospective studies. We excluded case-reports and studies
conducted on less than 10 patients. We classified the studies
in accordance with the AAN classification of evidence for
therapeutic intervention (Table 1) [9]. A total of five papers
were reviewed.
Results
We found two RCTs, a post-hoc subset analysis of 51
adolescents (12–17 years) who had been enrolled in three
pivotal RCTs of topiramate for migraine prophylaxis in
adults and two open studies.
In a recent Class I randomized, double-blind, placebo-
controlled trial [10], 44 children were randomized (in a 1:1
ratio) to receive either placebo or topiramate (titrated to
100 mg a day) for 12 weeks. Participants had a diagnosis
of migraine without aura (according to 2004 International
Headache Society criteria) [11] and a frequency of two or
more headaches per month for 3 months before entering
the study. Children with comorbid medical associations or
who were already on migraine prophylaxis were excluded.
Primary outcome measures were the reduction in migraine
frequency and severity; secondary outcome measures
included number of analgesics taken and the functional
disability. Migraine monthly frequency decreased from
16.14 (±9.35) at baseline to 4.27 (±1.95) at the end of the
study in the treated group as compared with a decrease
from 13.38 (±7.78) to 7.48 (±5.94) in the placebo group
(P = 0.025). The percentage of topiramate-treated subjects
showing[50% reduction in monthly migraine days during
the double-blind phase was 95.2% as opposed to 52.4% in
the placebo group (P = 0.002). The Pediatric Migraine
Disability Assessment Score (PedMIDAS) also decreased
significantly (P = 0.003) as did school absenteeism
(P = 0.002). Side effects were rated mild to moderate, did
not interfere with daily activities or cause any dropouts and
included weight-loss (mean loss of 0.3 kg) in 81% of
patients, paresthesia (23.8%), loss of appetite (23.8%), lack
of concentration (19%), sedation (19%) and abdominal
pain (14.3%). This seems a well-performed trial in which
the mean monthly migraine frequency reduction is clearly
evident in the topiramate-treated group. Patients treated
with topiramate suffered at least five episodes a month
before entering the study (range 5–30); a preventive
treatment was, thus, clearly indicated. The reduction in the
PedMIDAS score indicates that the drug side effects (dif-
ficulties in concentrating, sedation) interfered with school,
household or social activities to a lesser extent than the
migraine episodes.
The other Class I, randomized, double-blind, placebo-
controlled trial [12] was carried out on 162 children (age 6–
15 years) who were randomized in a 2:1 ratio to receive
either topiramate (which was titrated over 8 weeks to 2–
3 mg/kg per day and maintained for 12 weeks) or placebo.
Eligible criteria were the children with migraine with or
without aura, weighing more than 20 kg, who experienced
3–10 migraine days/month for the 3 months prior to the
screening and during the 4-week prospective baseline
phase. Exclusion criteria included chronic migraine, anal-
gesic overuse and previous failure of C2 adequately dosed
migraine preventive medications. One hundred and fifty-
seven subjects were included in the intention to treat (ITT)
population, defined as randomized subjects who had
Table 1 AAN classification of evidence for therapeutic intervention
Class I: Prospective, randomized, controlled clinical trial with masked
outcome assessment, in a representative population.
The following are required:
(a) Primary outcome(s) is/are clearly defined
(b) Exclusion/inclusion criteria are clearly defined
(c) Adequate accounting for drop-outs and crossovers with numbers
sufficiently low to have minimal potential for bias
(d) Relevant baseline characteristics are presented and substantially
equivalent among treatment groups or there is appropriate
statistical adjustment for differences
Class II: Prospective matched group cohort study in a representative
population with masked outcome assessment that meets (a)–(d)
above OR a RCT in a representative population that lacks one
criteria (a)–(d).
Class III: All other controlled trials (including well-defined natural
history controls or patients serving as own controls) in a
representative population, where outcome is independently
assessed, or independently derived by objective outcome
measurement.
Class IV: Evidence from uncontrolled studies, case series, case
reports, or expert opinion.
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received at least one dose of study medication and had at
least one postbaseline efficacy assessment, and a total of
131 children completed the study (per-protocol popula-
tion); of these, 108 were treated with topiramate. Primary
outcome measure was the reduction of migraine days per
month in each treatment group of the ITT population.
During the double-blind-phase, relative to the 4-week
prospective baseline phase, there was a reduction of
2.6 ± 2.6 migraine days per month in the topiramate group
compared with a mean reduction of 2.0 ± 3.1 migraine
days per month in the placebo group (P = 0.061). In the
per-protocol population, the reduction in monthly migraine
days (2.8 ± 2.4 as opposed to 2.2 ± 2.1 in the placebo
group) reached statistical significance (P = 0.033). During
the last 28 days of treatment, the mean number of monthly
migraine was reduced by 3.1 ± 2.6, as opposed to
2.4 ± 2.8 in the placebo group (P = 0.023). In the treated
group, 32% of patients experienced a C75% reduction in
mean monthly migraine days compared with a 14%
reduction in the placebo group (P = 0.02). The dropout
rate for adverse events was 6.3% for the topiramate group
and 4% for the placebo group. In the treated group, the
most common adverse events were anorexia (13%); weight
decrease (10.2%), with a mean loss of 1.4 ± 2.6 kg (as
opposed to 0.7 ± 3.9 kg in the placebo group); abdominal
pain (10.2%); paresthesia (8.3%); and somnolence (8.3%).
Serious adverse events occurred in four topiramate-treated
patients and included infection (n = 2), severe migraine
(n = 1) and suicidal ideation (n = 1).
In this study, the mean monthly migraine frequency
reduction seems less evident when compared to the pre-
vious study [10], probably because migraine frequency at
baseline was lower (range 2–9 in the ITT topiramate
population) and children with chronic migraine were
excluded. An important aspect is that the reduction is more
evident in the last 28 days of treatment, indicating that it
may take a few weeks before treatment with topiramate
reaches its maximum efficacy.
Winner et al. [13] performed a post-hoc subset analysis
on 51 adolescents (12–17 years) who had been enrolled in
three pivotal trials of topiramate for migraine prophylaxis
in adults. Patients were to have had between 3 and 12
migraine attacks, and no more than 14 headache days per
28 days during the 3 months prior to the screening and
during the 4-week prospective baseline phase. Also
excluded were patients who overused analgesics or who
had failed to respond to two or more adequate prophylactic
treatments. Topiramate was administered at the dosages of
50, 100 or 200 mg a day for 26 weeks. When compared to
baseline, there was a mean monthly migraine frequency
reduction of 46, 63 and 65%, respectively, as opposed to a
mean 16% reduction in the placebo group (P = 0.07,
P = 0.02, P = 0.04, respectively). The most common
adverse events (in the group treated with 100 mg a day)
were as follows: paresthesia (38%), upper respiratory tract
infections (23%), weight decrease (15%), abdominal pain
(15%), anorexia (8%) and somnolence (8%). There were no
dropouts in the group treated with topiramate. The inci-
dence of adverse events was higher in the group treated
with topiramate at the dosage of 200 mg, which did not
appear to confer additional efficacy as opposed to the
dosage of 100 mg a day.
One class IV study [14], assessing the efficacy of topi-
ramate for pediatric migraine, included 97 children, 75 of
which were reevaluated at a first follow-up visit (after
88.7 ± 35.7 days) and 41 at a second follow-up visit (after
203.1 ± 45.6 days). Included were children reporting more
than three headaches per month. Topiramate was admin-
istered at the dose of 1.4 ± 0.74 mg/kg/day and headache
frequency decreased from 16.5 ± 10 headaches/month to
11.6 ± 10.2 headaches/month (P \ 0.001) at the first fol-
low-up visit, with 43.1% of the patients experiencing a
50% or greater reduction in the number of headaches. By
the second follow-up visit, headache frequency had
decreased to 9.4 ± 8.4, with 56.1% of the patients expe-
riencing a 50% or greater reduction in the number of
headaches. Mean headache severity, duration and accom-
panying disability were also reduced. Disability was
measured using the PedMIDAS score: a 50% reduction
occurred in 48.6% of the patients at the first follow-up visit
and in 62.5% of patients at the second follow-up visit. One
quarter of patients complained of side effects, which
declined in subsequent visits and included cognitive
changes (12.5%), weight loss (5.6%) and sensory symp-
toms (2.8%). A possible bias of this study is that 50.7% of
patients were on additional prophylactic medication (most
often amitriptyline or divalproex).
In an open, prospective case series (class IV) study [15],
topiramate was administered to 24 children with migraine,
who had failed to respond to other prophylactics, at the
mean dosage of 3.5 ± 1.7 mg/kg for 4 months. Authors
report a reduction in the duration and in the intensity of
headaches; headache frequency reduction, however, did
not reach statistical significance. Adverse events (emo-
tional instability, paresthesia, anorexia, asthenia, weight
loss) were experienced by one-third of patients. In our
opinion, the baseline headache frequency (3.6 ± 2.7 a
month with a range of 1–12) and duration (2–6 h) did not
necessarily constitute an indication for prophylactic treat-
ment in all treated cases.
Unfortunately, the studies we reviewed were not
homogeneous with regard to inclusion and exclusion cri-
teria and with regard to outcome measures such as the
‘‘responder rate,’’ which was not considered in all studies.
Furthermore, the degree of disability caused by the
migraine episodes, which is essential in the decision to
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initiate prophylactic treatment, was not assessed in all
studies.
Discussion
Management of pediatric migraine can be tricky, seeing as
no pharmacological treatment is formally approved or
indicated in the prophylactic treatment of migraine in
children and adolescents. A recent review of the pharma-
cological treatment options in pediatric migraine [16]
found only flunarizine, which is not available in many
countries, to be effective in rigorous controlled trials.
Authors also concluded that there is conflicting evidence
regarding propanolol and trazodone, while data from
uncontrolled studies suggest cyproheptadine, amitriptyline,
naproxen and antiepileptic drugs (topiramate, valproic acid
and gabapentin) to be effective. Since this review was
published, two randomized, placebo-controlled trials eval-
uating topiramate in the preventive treatment of pediatric
migraine have been carried out [10, 12].
Taken together, data from the papers we reviewed
suggest that topiramate is effective in the preventive
treatment of pediatric migraine. Furthermore, topiramate
dosages, which seem to be effective in the treatment of
migraine in children and adolescents (2–3 mg/kg/day) are
much lower than those indicated for the adjunctive treat-
ment of epilepsy (5–9 mg/kg/day) in children as young as
2 years.
As regards its safety and tolerability, serious adverse
effects were very rare (one patient with suicidal ideation),
though the risk of depression must be kept in mind. The
percentage of patients experiencing side effects varied
greatly among the studies, the most common ones being
weight loss (which, in the RCTs [10, 12], was present in 81
and 10.2% of patients, respectively), anorexia (23.8 and
13%, respectively), abdominal pain (14.3 and 10,2%),
difficulties in concentrating, somnolence/sedation (19 and
8.3%) and paresthesia (23.8 and 8,3%). Side effects tended
to decline over time and dropout rates due to side effects
were very low (range 0–6.3%). Since these adverse events,
although often transitory, may be clinically significant and
distressing both for the child and its family, the decision to
initiate treatment must be carefully weighed and should
take the degree of disability caused by the migraine epi-
sodes into account.
An important aspect, which emerged from some of the
studies, is a significant decrease in school absenteeism due
to migraine [10] and a reduction in the disability caused by
migraine (as assessed by PedMIDAS), leading to an
improvement in the childrens’ quality of life [10, 14].
In conclusion, topiramate seems to be a promising
therapeutic option, though, clearly, further controlled trials
are needed to confirm this data, as are studies comparing
different drugs.
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